Eva Trevisson

Prof. Eva Trevisson

Department of Women's and Children's Health, University of Padova
orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 May 2011 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
SHSaskia F. Heeringa
Saskia F. Heeringa
GCGil Chernin
Gil Chernin
MCMoumita Chaki
Moumita Chaki
WZWeibin Zhou
Weibin Zhou
ASAlexis J. Sloan
Alexis J. Sloan
FHFriedhelm Hildebrandt
Friedhelm Hildebrandt
Steroid-resistant nephrotic syndrome (SRNS) is a frequent cause of end-stage renal failure. Identification of single-gene causes of SRNS has generated some insights into its pathogenesis; however, additional genes and disease mechanisms remain obscure, and SRNS continues to be treatment refractory. Here we have identified 6 different mutations in coenzyme Q10 biosynthesis monooxygenase 6 (COQ6) in 13 individuals from 7 families by homozygosity mapping. Each mutation was linked to early-onset SRNS with sensorineural deafness. The deleterious effects of these human COQ6 mutations were validated by their lack of complementation in coq6-deficient yeast. Furthermore, knockdown of Coq6 in podocyte cell lines and coq6 in zebrafish embryos caused apoptosis that was partially reversed by coenzyme Q10 treatment. In rats, COQ6 was located within cell processes and the Golgi apparatus of renal glomerular podocytes and in stria vascularis cells of the inner ear, consistent with an oto-renal disease phenotype. These data suggest that coenzyme Q10–related forms of SRNS and hearing loss can be molecularly identified and potentially treated.

1 February 2006 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
CQCatarina Quinzii
Catarina Quinzii
ANAli Naini
Ali Naini
LSLeonardo Salviati
Leonardo Salviati
Eva TrevissonEva Trevisson
Eva Trevisson
PNPlácido Navas
Plácido Navas
MHMichio Hirano
Michio Hirano

1 August 2016 in Biochimica et Biophysica Acta (BBA) - Bioenergetics
Verified
Journal Article
Closed access
MAManuel Jesús Acosta
Manuel Jesús Acosta
LVLuis Vazquez-fonseca
Luis Vazquez-fonseca
MDMaria Andrea Desbats
Maria Andrea Desbats
CCCristina Cerqua
Cristina Cerqua
RZRoberta Zordan
Roberta Zordan
LSLeonardo Salviati
Leonardo Salviati

1 January 2018 in The American Journal of Human Genetics
Verified
Journal Article
Open access
MKMagdalena Koczkowska
Magdalena Koczkowska
YCYunjia Chen
Yunjia Chen
TCTom Callens
Tom Callens
AGAlicia Gomes
Alicia Gomes
ASAngela Sharp
Angela Sharp
LMLudwine M. Messiaen
Ludwine M. Messiaen
Neurofibromatosis type 1 (NF1), a common genetic disorder with a birth incidence of 1:2,000-3,000, is characterized by a highly variable clinical presentation. To date, only two clinically relevant intragenic genotype-phenotype correlations have been reported for NF1 missense mutations affecting p.Arg1809 and a single amino acid deletion p.Met922del. Both variants predispose to a distinct mild NF1 phenotype with neither externally visible cutaneous/plexiform neurofibromas nor other tumors. Here, we report 162 individuals (129 unrelated probands and 33 affected relatives) heterozygous for a constitutional missense mutation affecting one of five neighboring NF1 codons-Leu844, Cys845, Ala846, Leu847, and Gly848-located in the cysteine-serine-rich domain (CSRD). Collectively, these recurrent missense mutations affect ∼0.8% of unrelated NF1 mutation-positive probands in the University of Alabama at Birmingham (UAB) cohort. Major superficial plexiform neurofibromas and symptomatic spinal neurofibromas were more prevalent in these individuals compared with classic NF1-affected cohorts (both p < 0.0001). Nearly half of the individuals had symptomatic or asymptomatic optic pathway gliomas and/or skeletal abnormalities. Additionally, variants in this region seem to confer a high predisposition to develop malignancies compared with the general NF1-affected population (p = 0.0061). Our results demonstrate that these NF1 missense mutations, although located outside the GAP-related domain, may be an important risk factor for a severe presentation. A genotype-phenotype correlation at the NF1 region 844-848 exists and will be valuable in the management and genetic counseling of a significant number of individuals.

6 October 2007 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
KDKai Stefan Dimmer
Kai Stefan Dimmer
FNFrancesca Navoni
Francesca Navoni
ACAlberto Casarin
Alberto Casarin
Eva TrevissonEva Trevisson
Eva Trevisson
SESabine Endele
Sabine Endele
Luca ScorranoLuca Scorrano
Luca Scorrano
Wolf–Hirschhorn syndrome (WHS) is a complex congenital syndrome caused by a monoallelic deletion of the short arm of chromosome 4. Seizures in WHS have been associated with deletion of LETM1 gene. LETM1 encodes for the human homologue of yeast Mdm38p, a mitochondria-shaping protein of unclear function. Here we show that human LETM1 is located in the inner membrane, exposed to the matrix and oligomerized in higher molecular weight complexes of unknown composition. Down-regulation of LETM1 did not disrupt these complexes, but led to DRP1-independent fragmentation of the mitochondrial network. Fragmentation was not associated with changes in the levels of respiratory chain complexes, or with obvious or latent mitochondrial dysfunction, but was recovered by nigericin, which catalyzes the electroneutral exchange of K+ against H+. Down-regulation of LETM1 caused ‘necrosis-like’ death, without activation of caspases and not inhibited by overexpression of Bcl-2. Primary fibroblasts from a WHS patient displayed reduced LETM1 mRNA and protein, but mitochondrial morphology was surprisingly unaffected, raising the question of whether and how WHS patients counteract the consequences of monoallelic deletion of LETM1. LETM1 highlights the relationship between mitochondrial ion homeostasis, integrity of the mitochondrial network and cell viability.

20 March 2007 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
JLJosé M. López-Martín
José M. López-Martín
LSLeonardo Salviati
Leonardo Salviati
Eva TrevissonEva Trevisson
Eva Trevisson
GMGiovanni Montini
Giovanni Montini
SDSalvatore DiMauro
Salvatore DiMauro
PNPlácido Navas
Plácido Navas
Coenzyme Q10 (CoQ10) deficiency has been associated with an increasing number of clinical phenotypes that respond to CoQ10 supplementation. In two siblings with encephalomyopathy, nephropathy and severe CoQ10 deficiency, a homozygous mutation was identified in the CoQ10 biosynthesis gene COQ2, encoding polyprenyl-pHB transferase. To confirm the pathogenicity of this mutation, we have demonstrated that human wild-type, but not mutant COQ2, functionally complements COQ2 defective yeast. In addition, an equivalent mutation introduced in the yeast COQ2 gene also decreases both CoQ6 concentration and growth in respiratory-chain dependent medium. Polyprenyl-pHB transferase activity was 33–45% of controls in COQ2 mutant fibroblasts. CoQ-dependent mitochondrial complexes activities were restored in deficient fibroblasts by CoQ10 supplementation, and growth rate was restored in these cells by either CoQ10 or uridine supplementation. This work is the first direct demonstration of the pathogenicity of a COQ2 mutation involved in human disease, and establishes yeast as a useful model to study human CoQ10 deficiency. Moreover, we demonstrate that CoQ10 deficiency in addition to the bioenergetics defect also impairs de novo pyrimidine synthesis, which may contribute to the pathogenesis of the disease.